$LFMD

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD, Inc. (Nasdaq: LFMD) said its board authorized a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) of $0.5546875 per share. The dividend will be paid July 15, 2026, to holders of record as of July 3, 2026.

Original reporting
Published Jun 23, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock — source image
Decision brief

The 30-second read

$LFMDNeutralLow
01

Why it matters

The declaration confirms a scheduled cash payout amount and key dates, which can affect preferred valuation and near-term income expectations, but provides no new operating or financial guidance.

02

Market read

A routine preferred dividend declaration with explicit per-share amount and payment/record dates; most relevant for preferred holders rather than common equity traders.

03

What to watch

Traders in preferreds may focus more on yield/price mechanics and any concurrent liquidity or refinancing context not provided here.

Relevance 4/10Novelty 5/10Timing: dividend payable July 15, 2026; holders of record July 3, 2026

Background

LifeMD (LFMD) announced a board-authorized cash dividend tied to its 8.875% Series A cumulative perpetual preferred stock (LFMDP).

Company-level read

Ticker impact

$LFMDNeutralMedium confidence
Context

LifeMD authorized a cash dividend on its 8.875% Series A cumulative perpetual preferred stock, with $0.5546875 per share payable July 15, 2026.

Expected impact

Likely limited impact on common shares; more noticeable for LFMDP preferred pricing around the record/payment dates.

Evidence & confidence

The release is a routine preferred dividend declaration with specified per-share amount and dates, but it does not include earnings, guidance, or balance-sheet changes.

Market effects

Minimal read-across to telehealth peers; this is company-specific capital return on preferred equity.

None indicated.

None indicated.

Counterpoint

Common equity may not react meaningfully because the dividend is on preferred stock, not a new common dividend or earnings update.

Key entities

  • LifeMD, Inc.

    Direct-to-patient telehealth company that authorized the preferred dividend.

  • 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP)

    Preferred series on which the cash dividend is declared.

Related articles

$LFMDMed

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

$TMed

AT&T Waives $19 LifeMD Fee for 100 Million Wireless and Fiber Customers

AT&T is partnering with LifeMD to waive its $19 monthly membership fee for over 100 million wireless and fiber customers, making it the first carrier to bundle no-cost virtual healthcare access. The rollout begins in 11 states, with the rest following in January 2027. LifeMD (LFMD) provides telehealth services, and AT&T aims to enhance customer retention. AT&T's stock is valued at $29.03 per share, with projected slight earnings declines due to heavy capital spending.

$LFMDMedAI 9/10

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

$LFMDHighAI 9/10

LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

$LFMDMed

LifeMD Reports Second Quarter 2026 Results

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately

$LLYHigh

Eli Lilly Invests $5bn in Virginia

Eli Lilly is investing $5bn in a new production site in Virginia, part of a $50bn plan to expand US drug manufacturing. The facility will be the company's first fully integrated plant, producing both APIs and finished drugs. It is the tenth new US site since 2020.